Apyx Medical: Customer Relationships That Underwrite an OEM-and-Consumables Hybrid

Apyx Medical operates as an advanced-energy medical-device company that monetizes through two complementary channels: direct sales of its Helium Plasma Technology systems (Renuvion/J-Plasma) to physicians and surgical centers, and contract manufacturing/OEM supply agreements that produce generators and components for other device companies. Revenue is weighted toward hardware sales plus recurring single‑use handpieces and accessories, while a meaningful OEM manufacturing business provides multi‑year contractual revenue and capacity utilization. For investors evaluating APYX customer relationships, the mix of direct end‑user sales and long-term OEM contracts is the critical operating lens.

If you want structured, customer‑level exposure data for diligence, see the research portal at NullExposure.

How Apyx makes money and why customer relationships matter

Apyx’s core commercial engine combines capital equipment placements with follow‑on disposable sales. The company sells electrosurgical generators and handpieces directly in the U.S. and through distributors internationally, while its OEM business supplies generators and manufactured components under contract. According to APYX’s public filings for 2024, the Advanced Energy segment accounted for the majority of sales and included both durable systems and single‑use consumables, and the OEM/contract manufacturing business contributed a measurable portion of total consolidated revenue.

Key operating characteristics flow directly from this commercial structure:

• Contracting posture: Apyx runs multi‑year OEM agreements (including a disclosed 10‑year manufacturing and supply contract), and the majority of customer orders are evidenced by firm purchase orders, creating predictability in manufacturing throughput.
• Revenue concentration and geography: The business is global — international sales were 29.3% of revenues in 2024 while domestic sales comprised the balance — so relationships span direct physician customers, surgical centers and distributor partners outside the U.S.
• Product criticality and margin profile: Hardware placements drive installed base growth; recurring revenue comes from single‑use handpieces and accessories that are highly profitable relative to equipment, making customer retention and consumable attachment rates a central margin lever.
• Maturity of relationships: OEM contracts and distributor agreements denote higher maturity and stickiness than one‑off equipment sales; manufacturing contracts are recorded as cost of sales and are contract‑driven rather than spot transactional.

For more on how customer relationships translate to financial exposure and concentration, consult NullExposure.

What the public record shows about Apyx’s customer mix

APYX’s disclosures and press coverage paint a consistent picture: the company is both a direct‑to‑physician seller in the U.S. and a contract manufacturer for large medical device partners, while relying on distribution channels internationally. The 2024 filing details split revenue lines and explicitly identifies OEM manufacturing as a distinct revenue segment that was 19.7% of consolidated total revenue for the referenced period. Outside the U.S., sales are routed primarily through distributors, while in the U.S. the company employs a direct sales force for its Renuvion system.

These characteristics produce an operating model where balance between consumable attach rates, distributor execution internationally, and the health of long‑term OEM contracts determines near‑term revenue growth and margin stability.

Customer relationship inventory (complete)

Below are the relationships surfaced by our review. Every relationship in the sourced results is covered.

Symmetry Surgical — 10‑year generator manufacturing and supply agreement (FY2025)

Apyx cites a long‑term manufacturing and supply agreement with Symmetry Surgical under which APYX supplies generators; the company noted that recent OEM volume declines excluded sales to Symmetry because that agreement remains in place, indicating Symmetry is a stable OEM counterparty under a multi‑year contract. This detail is stated on an earnings call transcript for Q1/FY2025. Source: an earnings call transcript published on InsiderMonkey discussing FY2025 commentary (March 2026).

Symmetry Surgical — historical Bovie core business transaction (FY2018)

A 2018 industry report records that Bovie divested its core business, including the Bovie brand, to Symmetry Surgical for $97 million — a transaction cited in coverage about APYX’s rebranding and corporate history. This earlier asset sale provides context for the historical commercial ties between the Bovie lineage and Symmetry Surgical. Source: MassDevice report on Bovie/APHX rebranding and industry transactions (2018).

What these relationships signal about risk and opportunity

• Stability via contracted OEM work: The explicit, long‑dated supply agreement with Symmetry is a structural hedge to OEM revenue volatility; multi‑year manufacturing contracts support capacity utilization and lend predictability to a business that also sells discrete capital equipment.
• Concentration and counterparty mix: The company serves both large enterprise OEMs and individual physician/surgery center end‑users; this diversified counterparty set reduces single‑channel risk but requires different commercial capabilities (enterprise contracting vs. clinical sales and training).
• International distribution dependence: With nearly 30% of sales outside the U.S., performance of distributor partners and local regulatory dynamics materially affect topline growth in those markets.
• Recurring revenue leverage: The model’s financial upside is anchored in consumables (single‑use handpieces and accessories), which convert installed base into steady aftermarket revenue — a characteristic that improves margin durability as installed systems scale.

Investment implications and diligence checklist

Investors and operators should prioritize three areas in ongoing diligence:

1. OEM contract terms and exposure: Review remaining duration, minimum purchase commitments, and termination provisions in major contracts such as the Symmetry agreement to assess revenue visibility and attrition risk.
2. Consumable attachment metrics: Track handpiece attach rates per installed generator and distributor sell‑through internationally; these drive margin expansion and recurring revenue growth.
3. Distributor performance and geographic mix: Monitor distributor channel execution in key geographies that together comprised nearly 30% of revenue in 2024; localized regulatory or reimbursement changes will influence growth.

For a deeper customer‑level exposure analysis, visit NullExposure and request the APYX customer brief.

Final takeaways

Apyx’s commercial model is dual‑anchored: direct capital equipment placements with recurring disposables, plus a contract manufacturing arm that supplies generators to large device partners under multi‑year agreements. The disclosed 10‑year agreement with Symmetry Surgical is an important structural element that reduces OEM revenue volatility, while international distributor reliance and the company’s consumables economics define the principal growth levers. Investors should focus diligence on contract durability, consumable economics, and distributor execution to understand how customer relationships translate into predictable cash flow.

For structured access to counterparty and customer relationship intelligence, including contract durations and exposure summaries, go to NullExposure.